New drugs for chemotherapy-naive patients with extensive-disease small cell lung cancer

Research output: Contribution to journalShort survey

Abstract

To improve the survival of patients with small cell lung cancer, there is a need for new and effective agents to treat this disease. These agents include paclitaxel, docetaxel, topotecan, irinotecan, vinorelbine, gemcitabine, and amrubicin. In previously untreated small cell lung cancer patients the response rate for these effective drugs ranges from 27% to 79%. Median survival ranges from 6.6 to 12 months. The major toxicity for these agents is leukopenia. Studies are ongoing to evaluate the efficacy of combination chemotherapy using new agents either together or with other known effective drugs for the treatment of small cell lung cancer.

Original languageEnglish (US)
Pages (from-to)27-29
Number of pages3
JournalSeminars in oncology
Volume28
Issue number2 SUPPL. 4
DOIs
StatePublished - 2001

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'New drugs for chemotherapy-naive patients with extensive-disease small cell lung cancer'. Together they form a unique fingerprint.

  • Cite this